EP0804590A1 - Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend - Google Patents

Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend

Info

Publication number
EP0804590A1
EP0804590A1 EP94918041A EP94918041A EP0804590A1 EP 0804590 A1 EP0804590 A1 EP 0804590A1 EP 94918041 A EP94918041 A EP 94918041A EP 94918041 A EP94918041 A EP 94918041A EP 0804590 A1 EP0804590 A1 EP 0804590A1
Authority
EP
European Patent Office
Prior art keywords
gene
selectable
cells
neo
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94918041A
Other languages
English (en)
French (fr)
Inventor
Stephen D. Lupton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ampliphi Biosciences Corp
Original Assignee
Targeted Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Genetics Corp filed Critical Targeted Genetics Corp
Publication of EP0804590A1 publication Critical patent/EP0804590A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates generally to genes expressing selectable phenotypes.
  • the present invention relates to genes capable of co-expressing both domina positive selectable and negative selectable phenotypes.
  • Genes which express a selectable phenotype are widely used in recombinant DNA technology as a means for identifying and isolating host cells into which the gene has been introduced.
  • the gene expressing the selectable phenotype is introduced into the host cell as part of a recombinant expression vector.
  • Positive selectable genes provide a means to identify and/or isolate cells that have retained introduced genes in a stable form, and, in this capacity, have greatly facilitated gene transfer and the analysis of gene function.
  • Negative selectable genes provide a means for eliminating cells that retain the introduced gene.
  • genes which confer selectable phenotypes on animal cells.
  • the bacterial neomycin phosphotransferase (neo) Coldbere-Garapin et al., J. Mol. Biol. 150:1, 1981
  • hph hygromycin phosphotransferase
  • gpt xanthine-guanine phosphoribosyl transferase
  • HSV-I TK Herpes simplex virus type I thymidine kinase gene (Wigler et al., Cell 11:223, 1977); the cellular adenine phosphoribosyltransferase (APRT) (Wigler et al., Proc. Natl. Acad. Sci. USA 76: 1373, 1979); and hypoxanthine phosphoribosyltransferase (HPRT) genes (Jolly et al., Proc. Natl. Acad. Sci. USA 50:477, 1983) are commonly used recessive positive selectable genes. I general, dominant selectable genes are more versatile than recessive genes, because the use of recessive genes is limited to mutant cells deficient in the selectable function, whereas dominan genes may be used in wild-type cells.
  • HSV-I TK genes confer negative as well as positive selectable phenotypes, including the HSV-I TK, HPRT, APRT and gpt genes. These genes encode enzymes which catalyze the conversion of nucleoside or purine analogs to cytotoxic inte ⁇ nediates.
  • the nucleoside analog ganciclovir (GCV) is an efficient substrate for HSV-I TK, but a poor substrate for cellular TK, and therefore may be used for negative selection against the HSV-I TK gene in wild-type cells (St. Clair et al., Antimicrob. Agents Chemother. 5 :844, 1987). However, the HSV-I TK gene may only be used effectively for positive selection in mutant cells lacking cellular TK activity.
  • HPRT and APRT genes for either positive or negative selection is similarly limited to HPRT “ or APRT " cells, respectively (Fenwick, "The HGPRT System", pp. 333-373, M. Gottesman (ed.), Molecular Cell Genetics, John Wiley and Sons, New York, 1985; Taylor et al., "The APRT System", pp. 311-332, M. Gottesman (ed.), Molecular Cell Genetics, John Wiley and Sons, New York, 1985).
  • the gpt gene may be used for both positive and negative selection in wild-type cells.
  • Negative selection against the gpt gene in wild-type cells is possible using 6-thioxanthine, which is efficiently converted to a cytotoxic nucleotide analog by the bacterial gpt enzyme, but not by the cellular HPRT enzyme (Besnard et al., Mol. Cell. Biol. 7:4139, 1987).
  • the bacterial cytosine deaminase (CD) gene converts 5- fluorocytosine (5-FC) to 5-fluorouracil (5-FU).
  • 5-FU is further metabolized intracellularly to 5-fluoro-uridine-5'-triphosphate and 5-fluoro-2'-deoxy-uridine-5'-monophosphate, which inhibit RNA and DNA synthesis, causing cell death.
  • 5-FC can effectively ablate cells carrying and expressing the CD gene.
  • the CD gene is not positively selectable in normal cells.
  • Gene therapy can be used as a means for augmenting normal cellular function, for example, by introducing a heterologous gene capable of modifying cellular activities or cellular phenotype, or alternatively, expressing a drug needed to treat a disease. Gene therapy may also be used to treat a hereditary genetic disease which results from a defect in or absence of one or more genes. Collectively, such diseases result in significant morbidity and mortality.
  • Examples of such genetic diseases include hemophilias A and B (caused by a deficiency of blood coagulation factors Vm and DC, respectively), alpha- 1-antitrypsin deficiency, and adenosine deaminase deficiency.
  • the missing gene has been identified and its complementary DNA (cDNA) molecularly cloned (Wood et al., Nature 312:330, 1984; Anson et al., Nature
  • the process of gene therapy typically involves the steps of (1) removing somatic (non- germ) cells from the patient, (2) introducing into the cells ex vivo a therapeutic or replacement gene via an appropriate vector capable of expressing the therapeutic or replacement gene, and (3) transplanting or transfusing these cells back into the patient, where the therapeutic or replacement gene is expressed to provide some therapeutic benefit.
  • Gene transfer into somatic cells for human gene therapy is presently achieved ex vivo (Kasid et al., Proc. Natl. Acad. Sci. USA 87:413, 1990; Rosenberg et al., N. Engl. J. Med.
  • genetically modified cells may actually compromise the health of the patient.
  • the ability to selectively eliminate genetically modified cells in vivo would provide an additional margin of safety for patients undergoing gene therapy, by permitting reversal of the procedure.
  • This might be accomplished by incorporating into the vector a negative selectable (or "suicide") gene that is capable of functioning in wild-type cells.
  • Incorporation of a gene capable of conferring both dominant positive and negative selectable phenotypes would ensure co-expression and co-regulation of th positive and negative selectable phenotypes, and would minimize the size of the vector.
  • positive selection for the gpt gene in some instances requires precise selection conditions which may be difficult to determine. For these reasons, co-expression of a dominan positive selectable phenotype and a negative selectable phenotype is typically achieved by co- expressing two different genes which separately encode other dominant positive and negative selectable functions, rather than using the gpt gene.
  • the present invention provides a method for more efficiently and reliably co-expressin a dominant positive selectable phenotype and a negative selectable phenotype encoded by different genes.
  • the present invention provides a selectable fusion gene comprising a dominant positiv selectable gene fused to and in reading frame with a negative selectable gene.
  • the selectable fusion gene encodes a single bifunctional fusion protein which is capable of conferring a dominant positive selectable phenotype and a negative selectable phenotype on a cellular host.
  • the selectable fusion genes of the present invention comprise nucleotide sequences for negativ selection that are derived from the bacterial cytosine deaminase (CD) gene.
  • the selectable fusion gene comprises nucleotide sequences from the bacterial CD gene fused to nucleotide sequences from the neo gene, referred to herei as the CD-neo selectable fusion gene (Sequence Listing No. 1).
  • the CD-neo selectable fusion gene confers both G-418 resistance (G-418 ) for dominant positive selection and 5- fluorocytosine sensitivity (5-FC ) for negative selection.
  • the present invention also provides recombinant expression vectors, for example, retroviruses, which include the selectable fusion genes, and cells transduced with the recombinant expression vectors.
  • FIG. 1 shows diagrams of the expression cassettes contained in plasmids tgCMV/hygro/LTR, tgCMV/neo, tgCMV/hygro-CD, tgCMV/CD-hygro, tgCMV/neo-CD and tgCMV/CD-neo.
  • the horizontal arrows indicate transcriptional start sites and direction of transcription.
  • the open box labeled LTR is the retroviral long terminal repeat.
  • the open box labeled CMV is the cytomegalovirus promoter.
  • Figure 2 shows the results of the cytosine deaminase assay on extracts prepared from transfected pools of NIH/3T3 cells. The extracts were assayed by measuring the conversion o cytosine to uracil.
  • Figure 3 shows diagrams of the proviral structures of retroviral vectors tgLS(+)neo an tgLS(+)CD-neo used in the present invention.
  • Figure 4 shows the results of the cytosine deaminase assay on uninfected (lane 1), tgLS(+)neo-infected (lane 2) and tgLS(+)CD-neo-infected NIH/3T3 (lane 3) cell pools. The results indicate that cells infected with the tgLS(+)CD-neo express high levels of cytosine deaminase activity.
  • Figure 5 shows photographs of stained colonies of uninfected NIH/3T3 cells (plates a, and c) and NIH/3T3 cells infected with the tgLS(+)neo (plates d and e) or tgLS(+)CD-neo (plates f and g) retroviruses.
  • the cells were grown in medium alone (plate a) or medium supplemented with G-418 (plates b, d and f) or G-418+5-FC (plates c, e and g) in a long-term proliferation assay.
  • NIH/3T3 cells were sensitive to G-418 and resistant to 5-FC
  • NIH/3T3 cells infected with tgLS(+)neo are resistant to both G-418 and 5- FC
  • NIH/3T3 cells infected with tgLS(+)CD-neo are resistant to G-418 and sensitive to 5- FC.
  • SEQ ID NO:l and SEQ ID NO:2 show specific embodiments of the nucleotide sequence and corresponding amino acid sequence of the CD-neo selectable fusion gene of the present invention.
  • the CD-neo selectable fusion gene shown in the Sequence Listing comprises sequences from the CD gene (nucleotides 4-1281) linked to sequences from the neo gene (nucleotides 1282-2073).
  • selectable fusion gene refers to a nucleotide sequence comprising a dominant positive selectable gene which is fused to and in reading frame with a negative selectable gene and which encodes a single bifunctional fusion protein which is capabl of conferring a dominant positive selectable phenotype and a negative selectable phenotype on cellular host.
  • a "dominant positive selectable gene” refers to a sequence of nucleotides which encodes a protein conferring a dominant positive selectable phenotype on a cellular host, and i discussed and exemplified in further detail below.
  • a “negative selectable gene” refers to a sequence of nucleotides which encodes a protein conferring a negative selectable phenotype on a cellular host, and is also discussed and exemplified in further detail below.
  • a “selectable gene” refers generically to dominant positive selectable genes and negative selectable genes.
  • a selectable gene is "fused to and in reading frame with" another selectable gene if the expression products of the selectable genes (i.e., the proteins encoded by the selectable genes) are fused by a peptide bond and at least part of the biological activity of each of the two proteins is retained.
  • the CD gene (encoding cytosine deaminase, which confers a negative selectable phenotype of 5- fluorocytosine sensitivity, or 5-FC j is fused to and in reading frame with the neo gene (encoding neomycin phosphotransferase, which confers the dominant positive selectable phenotype of G-418 resistance, or G-418 ) if the CD and neo proteins are fused by a peptide bond and expressed as a single bifunctional fusion protein.
  • the component selectable gene sequences of the present invention are preferably contiguous; however, it is possible to construct selectable fusion genes in which the component selectable gene sequences are separated by internal nontranslated nucleotide sequences, such as introns.
  • selectable fusion genes are considered to be fused, provided that expression of the selectable fusion gene results in a single bifunctional fusion protein in which the expression products of the component selectable gene sequences are fused by a peptide bond.
  • Nucleotide sequence refers to a heteropolymer of deoxyribonucleotides or ribonucleotides, such as a DNA or RNA sequence. Nucleotide sequences may be in the form of a separate fragment or as a component of a larger construct. Preferably, the nucleotide sequences are in a quantity or concentration enabling identification, manipulation, and recovery of the sequence by standard biochemical methods, for example, using a cloning vector. Recombinant nucleotide sequences are the product of various combinations of cloning, restriction, and ligation steps resulting in a construct having a structural coding sequence distinguishable from homologous sequences found in natural systems.
  • nucleotide sequences encoding the structural coding sequence can be assembled from nucleotide fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit.
  • sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes.
  • Genomic DNA containing the relevant selectable gene sequences is preferably used to obtain appropriate nucleotide sequences encoding selectable genes; however, cDNA fragments may also be used.
  • sequences of non ⁇ translated DNA may be present 5' or 3' from the open reading frame or within the open reading frame, provided such sequences do not interfere with manipulation or expression of the coding regions.
  • Some genes, however, may include introns which are necessary for proper expression in certain hosts, for example, the HPRT selectable gene includes introns which are necessary for expression in embryonal stem (ES) cells.
  • the nucleotide sequences of the present invention may also comprise RNA sequences, for example, where the nucleotide sequences are packaged as RNA in a retrovirus for infecting a cellular host. The use of retroviral expression vectors is discussed in greater detail below.
  • recombinant expression vector refers to a replicable unit of DNA or RNA in a form which is capable of being transduced into a target cell by transfection or viral infection, and which codes for the expression of a selectable fusion gene which is transcribed into mRNA and translated into protein under the control of a genetic element or elements having a regulatory role in gene expression, such as transcription and translation initiation and termination sequences.
  • the recombinant expression vectors of the present invention can take the form of DNA constructs replicated in bacterial cells and transfected into target cells directly, for example, by calcium phosphate precipitation, electroporation or other physical transfer methods.
  • RNA constructs may, for example, be in the form of infectious retroviruses packaged by suitable "packaging" cell lines which have previously been transfected with a proviral DNA vector and produce a retrovirus containing an RNA transcript of the proviral DNA.
  • a host cell is infected with the retrovirus, and the retroviral RNA is replicated by reverse transcription into a double-stranded DNA intermediate which is stably integrated into chromosomal DNA of the host cell to form a provirus.
  • the provirus DNA is then expressed in the host cell to produce polypeptides encoded by the DNA.
  • the recombinant expression vectors of the present invention thus include not only RNA constructs present in the infectious retrovirus, but also copies of proviral DNA, which include DNA reverse transcripts of a retrovirus RNA genome stably integrated into chromosomal DNA in a suitable host cell, or cloned copies thereof, or cloned copies of unintegrated intermediate forms of retroviral DNA.
  • Proviral DNA includes transcriptional elements in independent operative association with selected structural DNA sequences which are transcribed into mRNA and translated into protein when proviral sequences are expressed in infected host cells.
  • Recombinant expression vectors used for direct transfection will include DNA sequences enabling replication of the vector in bacterial host cells.
  • Various recombinant expression vectors suitable for use in the present invention are described below.
  • Transduce means introduction of a recombinant expression vector containing a selectable fusion gene into a cell. Transduction methods may be physical in nature (i.e., transfection), or they may rely on the use of recombinant viral vectors, such as retroviruses, encoding DNA which can be transcribed to RNA, packaged into infectious viral particles and used to infect target cells and thereby deliver the desired genetic material (i.e., infection). Many different types of mammalian gene transfer and recombinant expression vectors have been developed (see, e.g., Miller and Calos, Eds., "Gene Transfer Vectors for Mammalian Cells," Current Comm. Mol. Biol., (Cold Spring Harbor Laboratory, New York, 1987)).
  • Naked DNA can be physically introduced into mammalian cells by transfection using any one of a number of techniques including, but not limited to, calcium phosphate transfection (Berma et al., Proc. Natl. Acad. Sci. USA 84 81:7176, 1984), DEAE-Dextran transfection (McCutcha et al., J. Natl. Cancer Inst. 41:351, 1986; Luthman et al., Nucl. Acids Res. 77:1295, 1983), protoplast fusion (Deans et al., Proc. Natl. Acad. Sci. USA 84 81:1292, 1984), electroporation (Potter et al., Proc. Natl. Acad.
  • the viral vectors which have been used in this way include virus vectors derived from simian virus 40 (SV40; Karlsson et al., Proc. Natl. Acad. Sci. USA 84 82:158, 1985), adenoviruses (Karlsson et al., EMBO J. 5:2311, 1986), adeno-associated virus (LaFace et al., Virology 762:483, 1988) and retroviruses (Coffin, 1985, pl7-71 in Weiss et al. (eds.), RNA Tumor Viruses, 2nd ed. Vol 2, Cold Spring Harbor Laboratory, New York).
  • SV40 simian virus 40
  • Karlsson et al. Proc. Natl. Acad. Sci. USA 84 82:158, 1985
  • adenoviruses Kerlsson et al., EMBO J. 5:2311, 1986
  • adeno-associated virus La
  • gene transfer and expression methods are numerous but essentially function to introduce and express genetic material in mammalian cells
  • hematopoietic or lymphoid cells including calcium phosphate transfection (Berman et al., supra, 1984), protoplast fusion (Deans et al., supra, 1984), electroporation (Cann et al., Oncogene 5:123, 1988), and infection with recombinant adenovirus (Karlsson et al., supra; Reuther et al., Mol. Cell. Biol.
  • adeno-associated virus (LaFace et al., supra) and retrovirus vectors (Overell et al., Oncogene 4:1425, 1989).
  • Primary T lymphocytes have been successfully transduced by electroporation (Cann et al., supra, 1988) and by retroviral infection (Nishihara et al., Cancer Res. 48:4130, 1988; Kasid et al., supra, 1990).
  • the selectable fusion genes of the present invention comprise a dominant positive selectable gene fused to a negative selectable gene.
  • a selectable gene will generally comprise, for example, a gene encoding a protein capable of conferring an antibiotic resistance phenotype or supplying an autotrophic requirement (for dominant positive selection), or activating a toxic metabolite (for negative selection).
  • a DNA sequence encoding a bifunctional fusion protein is constructed using recombinant DNA techniques to assemble separate DNA fragments encoding a dominant positive selective gene and a negative selectable gene into an appropriate expression vector.
  • the 3' end of the one selectable gene is ligated to the 5' end of the other selectable gene, with the reading frames of the sequences in frame to permit translation of the mRNA sequences into a single biologically active bifunctional fusion protein.
  • the selectable fusion gene is expressed under control of a single promoter.
  • the dominant positive selectable gene is a gene which, upon being transduced into a host cell, expresses a dominant phenotype permitting positive selection of stable transductants.
  • the dominant positive selectable gene of the present invention is preferably selected from the group consisting of the aminoglycoside phosphotransferase gene (neo or aph) from Tn5 which codes for resistance to the antibiotic G418 (Colbere-Garapin et al., J. Mol. Biol. 750:1, 1981; Southern and Berg, J. Mol. Appl. Genet.
  • Hygromycin-B phosphotransferase gene (hph or "hygro") which confers the selectable phenotype of hygromycin resistance (Hm )
  • Hm hygromycin resistance
  • Hygromycin B is an aminoglycoside antibiotic that inhibits protein synthesis by disrupting translocation and promoting mistranslation.
  • the hph gene confers Hm to cells transduced with the hph gene by phosphorylating and detoxifying the antibiotic hygromycin B.
  • neomycin phosphotransferase Bacillus neo gene encoding neomycin phosphotransferase (Beck et al., Gene 19:321, 1982); the xanthine-guanine phosphoribosyl transferase gene (gpt) from E. coli encoding resistance to mycophenolic acid (Mulligan and Berg, Proc. Natl. Acad. Sci. USA 78:2012, 1981); the dihydrofolate reductase (DHFR) gene from murine cells or E.
  • gpt xanthine-guanine phosphoribosyl transferase gene
  • DHFR dihydrofolate reductase
  • coli which is necessary for biosynthesis of purines and can be competitively inhibited by the drug methotrexate (MTX) to select for cells constitutively expressing increased levels of DHFR (Simonsen and Levinson, Proc. Natl. Acad. Sci. USA 50:2495, 1983; Simonsen et al., Nucl. Acids Res. 76:2235, 1988); the 5. typhimurium histidin dehydrogenase (hisO) gene (Hartman et al., Proc. Natl. Acad. Sci.
  • MTX drug methotrexate
  • E coli tryptophan synthase ⁇ subunit (t B) gene (Hartman et al., supra); the puromycin-N-acetyl transferase (pad) gene (Vara et al., Nucl. Acids Res. 74:4117, 1986); the adenosine deaminase (ADA) gene (Daddona et al., J. Biol. Chem. 259:12101, 1984); the multi-drug resistance
  • MDR mouse ornithine decarboxylase
  • OCD mouse ornithine decarboxylase
  • pyr E. coli aspartate transcarbamylase catalytic subunit
  • E. coli asnA gene encoding asparagine synthetase (Cartier et al., Mol. Cell. Biol. 7:1623, 1987).
  • the negative selectable gene is a gene which, upon being transduced into a host cell, expresses a phenotype permitting negative selection (i.e., elimination) of stable transductants.
  • the preferred negative selectable gene of the present invention is the bacterial CD gene encoding cytosine deaminase (Genbank accession number X63656) which confers 5- fluorocytosine sensitivity.
  • enzymes suitable for negative selection include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs such as etoposide-phosphate, doxorubicin-phosphate, mitomycin phosphate, into toxic dephosphorylated metabolites; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; proteases, such as serratia protease, thermolysin, subtil isin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as 0-galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; 0-lactamase useful for converting drugs derivat
  • Other enzyme prodrug combinations include the bacterial (for example, from Pseudomonas) enzyme carboxypeptidase G2 with the prodrug para-N-bis(2-chloroethyl) aminobenzoyl glutamic acid. Cleavage of the glutamic acid moiety from this compound releases a toxic benzoic acid mustard. Penicillin- V amidase will convert phenoxyacetamide derivatives of doxorubicin and melphalan to toxic metabolites.
  • nucleotide sequences encoding the same amino acid sequence Due to the degeneracy of the genetic code, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence; exemplary DNA embodiments are those corresponding to the nucleotide sequences in Sequence Listing No. 1. Such variants will have modified DNA or amino acid sequences, having one or more substitutions, deletions, or additions, the net effect of which is to retain biological activity, and may be substituted for the specific sequences disclosed herein.
  • sequences of selectable fusion genes comprising CD and neo are equivalent if they contain all or part of the sequences of CD and neo and are capable of hybridizing to the nucleotide sequence of Sequence Listing No.
  • a biologically active fusion protein will share sufficient amino acid sequence similarity with the specific embodiments of the present invention disclosed herein to be capable of conferring the selectable phenotypes of the component selectable genes.
  • sequences from the bacterial cytosine deaminase (CD) gen are fused with sequences from the bacterial neomycin phosphotransferase (neo) gene.
  • the resulting selectable fusion gene (referred to as the CD-neo selectable fusion gene) encodes a r s bifunctional fusion protein that confers G-418 and 5-GC and provides a means by which dominant positive and negative selectable phenotypes may be expressed and regulated as a single genetic entity.
  • the CD-neo selectable fusion gene may be especially advantageous in patient populations likely to receive ganciclovir.
  • the selectable fusion genes of the present invention are utilized to identify, isolate or eliminate host cells into which the selectable fusion genes are introduced.
  • the selectable fusio genes are introduced into the host cell by transducing into the host cell a recombinant expression vector which contains the selectable fusion gene.
  • host cells include cell types from higher eukaryotic origin, such as mammalian or insect cells, or cell types from lower prokaryotic origin.
  • selectable fusion genes are preferably introduced into a particular cell as a component of a recombinant expression vector which is capable of expressing the selectable fusion gene within the cell and conferring a selectable phenotype.
  • Such recombinant expression vectors generally include synthetic or natural nucleotide sequence comprising the selectable fusion gene operably linked to suitable transcriptional or translational control sequences, for example, an origin of replication, optional operator sequences to control transcription, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.
  • suitable transcriptional or translational control sequences for example, an origin of replication, optional operator sequences to control transcription, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.
  • suitable transcriptional or translational control sequences
  • a promoter is operably linked to a selectable fusion gene if it controls the transcription of the selectable fusion gene; or a ribosome binding site is operably linked to a selectable fusion gene if it is positioned so as to permit translation of the selectable fusion gene into a single bifunctional fusion protein.
  • operably linked means contiguous.
  • recombinant expression vectors for use with mammalian, bacterial, and yeast cellular hosts are described by Pouwels et al. (Qoning Vectors: A Laboratory Manual, Elsevier, New York, 1985) and are well-known in the art. A detailed description of recombinant expression vectors for use in animal cells can be found in Rigby, J. Gen. Virol. 64:255, 1983); Elder et al., Ann. Rev. Genet. 75:295, 1981; and Subramani et al., Anal. Biochem. 755:1, 1983. Appropriate recombinant expression vectors may also include viral vectors, in particular retroviruses (discussed in detail below).
  • the selectable fusion genes of the present invention are preferably placed under the transcriptional control of a strong enhancer and promoter expression cassette.
  • expression cassettes include the human cytomegalovirus immediate-early (HCMV-IE) promoter (Boshart et al., Cell 41:521, 1985), the 3-actin promoter (Gunning et al., Proc. Natl. Acad. Sci. USA 54:5831, 1987), the histone H4 promoter (Guild et al., J. Virol. 62:3795, 1988), the mouse metallothionein promoter (Mclvor et al., Mol. Cell. Biol.
  • the rat growth hormone promoter (Miller et al., Mol. Cell Biol. 5:431, 1985), the human adenosine deaminase promoter (Hantzapoulos et al., Proc. Natl Acad. Sci. USA 56:3519, 1989) the HSV TK promoter (Tabin et al., Mol. Cell. Biol. 2:426, 1982), the ⁇ -1 antitrypsin enhancer (Peng et al., Proc. Natl. Acad. Sci. USA 55:8146, 1988) and the immunoglobulin enhancer/promoter (Blankenstein, et al., Nucleic Acid Res.
  • the SV40 early or late promoters the Adenovirus 2 major late promoter, or other viral promoters derived from polyoma virus, bovine papilloma virus, or other retroviruses or adenoviruses.
  • the promoter and enhancer elements of immunoglobulin (Ig) genes confer marked specificity to B lymphocytes (Banerji et al., Cell 55:729, 1983; Gillies et al., Cell 55:717, 1983; Mason et al., Cell 41:419, 1985), while the elements controlling transcription of the jS-globin gene function only in erythroid cells (van Assendelft et al., Cell 56:969, 1989).
  • transcriptional control sequences can be excised from various DNA sources and integrated in operative relationship with the intact selectable fusion genes to be expressed in accordance with the present invention.
  • many transcriptional control sequences may be used successfully in retroviral vectors to direct the expression of inserted genes in infected cells.
  • Retroviruses can be used for highly efficient transduction of the selectable fusion genes of the present invention into eukaryotic cells and are preferred for the delivery of a selectable fusion gene into primary cells. Moreover, retroviral integration takes place in a controlled fashion and results in the stable integration of one or a few copies of the new genetic information per cell. Retroviruses are a class of viruses whose genome is in the form of RNA. The genomic
  • RNA of a retrovirus contains tr ⁇ /w-acting gene sequences coding for viral proteins, including: structural proteins (encoded by the gag region) that associate with the RNA in the core of the virus particle; reverse transcriptase (encoded by the pol region) that makes the DNA complement; and an envelope glycoprotein (encoded by the env region) that resides in the lipoprotein envelope of the particles and binds the virus to the surface of host cells on infection.
  • Replication of the retrovirus is regulated by cw-acting elements, such as the promoter for transcription of the proviral DNA and other nucleotide sequences necessary for viral replication.
  • the cw-acting elements are present in or adjacent to two identical untranslated long terminal repeats (LTRs) of about 600 base pairs present at the 5' and 3' ends of the retroviral genome.
  • Retroviruses replicate by copying their RNA genome by reverse transcription into a double-stranded DNA intermediate, using a virus-encoded, RNA-directed DNA polymerase, or reverse transcriptase.
  • the DNA intermediate is integrated into chromosomal DNA of an avian or mammalian host cell.
  • the integrated retroviral DNA is called a provirus.
  • the provirus serves as template for the synthesis of RNA chains for the formation of infectious virus particles. Forward transcription of the provirus and assembly into infectious virus particles occurs in the presence of an appropriate helper virus having endogenous tr-a/is-acting genes required for viral replication.
  • Retroviruses are used as vectors by replacing one or more of the endogenous trans ⁇ acting genes of a proviral form of the retrovirus with a recombinant therapeutic gene or, in the case of the present invention, a selectable fusion gene, and then transducing the recombinant provirus into a cell.
  • the fr ⁇ /w-acting genes include the gag, pol and env genes which encode, respectively, proteins of the viral core, the enzyme reverse transcriptase and constituents of the envelope protein, all of which are necessary for production of intact virions.
  • Recombinant retroviruses deficient in the tr ⁇ /w-acting gag, pol or env genes cannot synthesize essential proteins for replication and are accordingly replication-defective.
  • Such replication-defective recombinant retroviruses are propagated using packaging cell lines.
  • These packaging cell lines contain integrated retroviral genomes which provide all tr ⁇ /w-acting gene sequences necessary for production of intact virions.
  • Proviral DNA sequences which are transduced into such packaging cells lines are transcribed into RNA and encapsidated into infectious virions containing the selectable fusion gene (and/or therapeutic gene), but, lacking the tr ⁇ /w-acting gene products gag, pol and env, cannot synthesize the necessary gag, pol and env proteins for encapsidating the RNA into particles for infecting other cells.
  • the resulting infectious retrovirus vectors can therefore infect other cells and integrate a selectable fusion gene into the cellular DNA of a host cell, but cannot replicate.
  • Mann et al. (Cell 55:153, 1983), for example, describe the development of various packaging cell lines (e.g., ⁇ 2) which can be used to produce helper virus-free stocks of recombinant retrovirus.
  • Encapsidation in a cell line harboring tr ⁇ m?-acting elements encoding an ecotropic viral envelope (e.g., ⁇ 2) provides ecotropic (limited host range) progeny virus.
  • assembly in a cell line containing amphotropic packaging genes e.g., PA317, ATCC CRL 9078; Miller and Buttimore, Mol. Cell. Biol. 6:2895, 1986) provides amphotropic (broad host range) progeny virus.
  • provirus constructs have been used successfully to express foreign genes (see, e.g., Coffin, in Weiss et al. (eds.), RNA Tumor Viruses, 2nd Ed., Vol. 2, (Cold Spring Harbor Laboratory, New York, 1985, pp. 17-71). Most proviral elements are derived from murine retroviruses. Retroviruses adaptable for use in accordance with the present invention can, however, be derived from any avian or mammalian cell source. Suitable retroviruses must be capable of infecting cells which are to be the recipients of the new genetic material to be transduced using the retroviral vector.
  • retroviruses examples include avian retroviruses, such as avian erythroblastosis virus (AEV), avian leukosis virus (ALV), avian myeloblastosis virus (AMV), avian sarcoma virus (ASV), Fujinami sarcoma virus (FuSV), spleen necrosis virus (SNV), and Rous sarcoma virus (RSV); bovine leukemia virus (BLV); feline retroviruses, such as feline leukemia virus (FeLV) or feline sarcoma virus (FeSV); murine retroviruses, such as murine leukemia virus (MuLV); mouse mammary tumor virus (MMTV), and murine sarcoma virus (MSV); and primate retroviruses, such as human T-cell lymphotropic viruses 1 and 2 (HTLV-1, and -2), and simian sarcoma virus (SSV).
  • AEV avian erythroblasto
  • retroviruses are known to those skilled in the art.
  • a taxonomy of retroviruses is provided by Teich, in Weiss et al. (eds.), RNA Tumor Viruses, 2d ed., Vol. 2 (Cold Spring Harbor Laboratory, New York, 1985, pp. 1-160).
  • Preferred retroviruses for use in connection with the present invention are the murine retroviruses known as Moloney murine leukemia virus (MoMLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMSV) and Kirsten murine sarcoma virus (KiSV).
  • MoMLV Moloney murine leukemia virus
  • MoMSV Moloney murine sarcoma virus
  • HaMSV Harvey murine sarcoma virus
  • Kirsten murine sarcoma virus KiSV
  • sequences required to construct a retroviral vector from the MoMSV genome can be obtained in conjunction with a pBR322 plasmid sequence such as pMV (ATCC 37190), while a cell line producer of KiSV in K-BALB cells has been deposited as ATCC CCL 163.3.
  • pRSVneo derived from pBR322 including the RSV LTR and an intact neomycin drug resistance marker is available from ATC under Accession No. 37198.
  • Plasmid pPBlOl comprising the SNV genome is available as ATCC 45012.
  • the viral genomes of the above retroviruses are used to construct replication- defective retrovirus vectors which are capable of integrating their viral genomes into the chromosomal DNA of an infected host cell but which, once integrated, are incapable of replication to provide infectious virus, unless the cell in which it is introduced contains other proviral elements encoding functional active tr ⁇ /w-acting viral proteins.
  • the selectable fusion genes of the present invention which are transduced by retroviruses are expressed by placing the selectable fusion gene under the transcriptional contro of the enhancer and promoter incorporated into the retroviral LTR, or by placing them under the control of heterologous transcriptional control sequences inserted between the LTRs.
  • Use of both heterologous transcriptional control sequences and the LTR transcriptional control sequences enables coexpression of a therapeutic gene and a selectable fusion gene in the vector, thus allowing selection of cells expressing specific vector sequences encoding the desired therapeutic gene product.
  • Obtaining high-level expression may require placing the therapeutic gene and/or selectable fusion gene within the retrovirus under the transcriptional control of a strong heterologous enhancer and promoter expression cassette.
  • heterologous enhancers and promoters have been used to express genes in retroviral vectors.
  • Such enhancer or promoters can be derived from viral or cellular sources, including mammalian genomes, an are preferably constitutive in nature.
  • Such heterologous transcriptional control sequences are discussed above with reference to recombinant expression vectors.
  • DNA sequences introduced by any of the above gene transfer methods are usually expressed under the control of an RNA polymerase ⁇ promoter.
  • Particularly preferred recombinant expression vectors include pLXSN, pLNCX and pLNL ⁇ , and derivatives thereof, which are described by Miller and Rosman, Biotechniques 7:980, 1989. These vectors are capable of expressing heterologous DNA under the transcriptional control of the retroviral LTR or the CMV promoter, and the neo gene under th control of the SV40 early region promoter or the retroviral LTR.
  • the neo gene is replaced with the bifunctional selectable fusion genes disclosed herein, such as the CD-neo selectable fusion gene. Construction of useful replication-defective retroviruses is a matter of routine skill.
  • the resulting recombinant retroviruses are capable of integration into the chromosomal DNA of an infected host cell, but once integrated, are incapable of replication to provide infectious virus, unless the cell in which it is introduced contains another proviral insert encoding functionally active trans-acting viral proteins.
  • the selectable fusion genes of the present invention are particularly preferred for use i gene therapy as a means for identifying, isolating or eliminating cells, such as somatic cells, into which the selectable fusion genes are introduced.
  • somatic cells are removed from a patient, transduced with a recombinant expression vector containing a therapeutic gene and the selectable fusion gene of the present invention, and then reintroduced back into the patient.
  • Somatic cells which can be used as vehicles for gene therapy include hematopoietic (bone marrow-derived) cells, keratinocytes, hepatocytes, endothelial cells and fibroblasts (Friedman, Science 244:1215, 1989).
  • gene therapy can be accomplished through the use of injectable vectors which transduce somatic cells in vivo.
  • injectable vectors which transduce somatic cells in vivo.
  • Rosenberg et al. N. Engl. J. Med. 525:570, 1990.
  • the selectable fusion genes of the present invention are particularly useful for eliminating genetically modified cells in vivo. In vivo elimination of cells expressing a negativ selectable phenotype is particularly useful in gene therapy as a means for ablating a cell graft, thereby providing a means for reversing the gene therapy procedure.
  • administration of the anti-herpes virus drug ganciclovir to transgenic animals expressing the HSV-I TK gene from an immunoglobulin promoter results in the selective ablation of cells expressing the HSV-I TK gene (Heyman et al., Proc. Natl. Acad. Sci. USA 56:2698, 1989).
  • GCV has also been shown to induce full regression of Abelson leukemia virus-induced lymphomas (Moolten et al., Human Gene Therapy 7:125, 1990).
  • a murine sarcoma K3T3 was infected with a retrovirus expressing HSV-I TK and transplanted into syngeneic mice
  • the tumors induced by the sarcoma cells were completely eradicated following treatment with GCV (Moolten and Wells, J. Natl. Cancer Inst. 52:297, 1990).
  • the selectable fusion genes of the present invention also are beneficial in tumor ablatio therapy as it has been practiced by Oldfield et al., Human Gene Therapy 4:39, 1993.
  • Packaging cells (about 10 - 10 ) producing the tgLS(+)CD-neo retroviral vectors are inoculated intra-tumorally. After a period of several days, during which the newly produced retroviruses infect the adjacent rapidly growing tumor cells, the patient is given about 50-200 mg of 5-FC per kg body weight (orally or intravenously) daily (when the tgLS(+)CD-neo retroviral vector has been used) to selectively ablate the infected tumor cells.
  • the bifunctional selectable fusion genes of the present invention can also be used to facilitate gene modification by homologous recombination. Reid et al., Proc. Natl. Acad. Sci.
  • a construct containing the desired replacement sequences embedded in the target gene sequences (but without the HPRT gene) is transfected into the cells and homologous recombinants having the replacement sequences (but not the HPRT gene) are isolated by negative selection against
  • HPRT cells Although this procedure allows the introduction of subtle mutations into a targe gene without introducing selectable gene sequences into the target gene, it requires positive selection of transfor ants in a HPRT cell line, since the HPRT gene is recessive for positive selection. Also, due to the inefficient expression of the HPRT gene in ES cells, it is necessary to use a large 9-kbp HPRT mini-gene which complicates the construction and propagation of homologous recombination vectors.
  • the selectable fusion genes of the present invention provide an improved means whereby "in-out" homologous recombination may be performed.
  • any wild-type cell may be used (i.e., one is not limited to use of cells deficient in the selectable phenotype).
  • the size of the vector containing the selectable fusion gene is reduced significantly relative to the large HPRT mini-gene.
  • the CD-neo selectable fusion gene is used as follows: In the first "in” step, the CD-neo selectable fusion gene is embedded in target gene sequences, transfected into a host cell, and homologous recombinants having incorporated the CD-neo selectable fusion gene into the target locus are identified by their growth in medium containing G-418 followed by genome analysis using PCR. The CD-neo cells are then used in the second "out” step, in which a construct containing the desired replacement sequences embedde in the target gene sequences (but without the CD-neo selectable fusion gene) is transfected into the cells. Homologous recombinants are isolated by selective elimination of CD-neo cells using 5-FC followed by genome analysis using PCR.
  • Plasmid tgCMV/hygro/LTR ( Figure 1) consists of the following elements: the Ball-Sst fragment containing the HCMV IE94 promoter (Boshart et al., Cell 41:521, 1985); an oligonucleotide containing a sequence conforming to a consensus translation initiation sequenc for mammalian cells (GCCGCCACC ATG) (Kozak et al., Nucl. Acids Res. 75:8125, 1987); nucleotides 234-1256 from the hph gene (Kaster et al., Nucl. Acids Res.
  • Plasmids tgCMV/neo, tgCMV/CD, tgCMV/CD-hygro, tgCMV/neo-CD, and tgCMV/CD-neo are all similar in structure to tgCMV/hygro/LTR and contain the consensus translation initiation sequence; however, each contains different sequences in place of the hph sequences.
  • Plasmid tgCMV/neo contains an oligonucleotide encoding three amino acids (GG TCG GCC) and nucleotide 154-945 from the bacterial neo gene encoding neomycin phosphotransferase (Beck et al., Gene 19:321, 1982), in place of the hph sequences.
  • Plasmid tgCMV/CD contains nucleotides 1645-2925 from the bacterial CD gene encoding cytosine deaminase (Genbank accession number X63656), in place of the hph sequences. The CD sequences were amplified by PCR from plasmid pCD2 (Mullen et al., Proc.
  • Plasmid tgCMV/hygro-CD contains nucleotides 234-1205 from the hph gene fused to nucleotides 1645-2925 from the CD gene in place of the hph sequences. Plasmi tgCMV/CD-hygro contains nucleotides 1645-2922 from the CD gene fused to nucleotides 234- 1256 from the hph gene in place of the hph sequences.
  • Plasmid tgCMV/neo-CD contains an oligonucleotide encoding an additional three amino acids (GGA TCG GCC) and nucleotides 154-942 from the bacterial neo gene fused to nucleotides 1645-2925 from the CD gene in plac of the hph sequences. Plasmid tgCMV/CD-neo contains nucleotides 1645-2922 from the CD gene fused to nucleotides 154-945 from the neo gene in place of the hph sequences.
  • Plasmid tgCMV/hygro/LTR was constructed using standard techniques (Ausubel et al., Current Protocols in Molecular Biology (Wiley, New York), 1987) as follows: Plasmid HyTK CMV-IL2 was constructed first by ligating the large Hind ⁇ l-Stul fragment from tgLS(+)HyT (Lupton et al., Mol. Cell. Biol. 77:3374, 1991) with the Hindl ⁇ -Stul fragment spanning the HCMV IE94 promoter from tgLS(-)CMV/HyTK (Lupton et al., supra, 1991), and a fragment containing human IL-2 cDNA sequences. The fragment containing human IL-2 cDNA sequences was amplified from a plasmid containing the human IL-2 cDNA by PCR using oligonucleotides
  • the PCR product was first treated with T4 DNA polymerase to render the ends blunt, then digested with Nhel, before ligation to the fragments from tgLS(+)HyTK and tgLS(-)CMV/HyTK.
  • a Pvul-Nhel fragment spanning the HCMV IE94 promoter from tgCMV/hygro was ligated to a Nhel-Hindi ⁇ fragment spanning the neo gene from tgLS(+)neo (the Hindlll site was treated with T4 DNA polymerase to render the end blunt) and ligated to Sall-Pvul fragment containing the Moloney leukemia virus LTR (which contains the retroviral polyadenylation signal) from HyTK-CMV-IL2.
  • Plasmid tgCMV/CD was constructed using standard techniques (Ausubel et al., supra, 1987) as follows: A Pvul-Nhel fragment spanning the HCMV IE94 promoter from tgCMV hygro was ligated to a synthetic DNA fragment (prepared by annealing oligonucleotide 5'-CTAGCCGCCACCATGTCGAATAACGCT ⁇ ACAAACAA ⁇ ATTAACGCCCG-3' and 5'-GTAACCGGGCGTTAATAATTGTTTGTAAAGCGTTATTCGACATGGTGGCGG-3 , ), th BstE2-AluI fragment containing the remainder of the CD coding region from pCD2 (Mullen et al., Proc.
  • Plasmid tgCMV/CD-hygro was constructed using standard techniques (Ausubel et al., supra, 1987) as follows: The large Clal-Sall fragment from tgCMV/CD was ligated to a Clal- Ncol fragment amplified from tgCMV/hygro by PCR using oligonucleotides 5'-CCCATCGATTACAAACGTAAAAAGCCTGAACTCACCGCGAC-3' and 5'-GCCATGTAGTGTATTGACCGATTCC-3' (the PCR product was digested with Clal and Ncol before ligation), and an Ncol-Sall fragment containing the remainder of the hph coding region from tgCMV/hygro/LTR.
  • Plasmid tgCMV/hygro-CD was constructed using standard techniques (Ausubel et al., supra, 1987) as follows: The large SpeI-BstE2 fragment from tgCMV/CD was ligated to a Spel-Scal fragment containing the hph coding region from tgCMV/hygro/LTR, and a synthetic DNA fragment (prepared by annealing oligonucleotides S'-ACTCTCGAATAACGCTTTACAAACAATTATTAACGCCCG-S' and S'-GTAACCGGGCGTTAATAATTGTTTGTAAAGCGTTATTCGAGAGT-S').
  • Plasmid tgCMV/CD-neo was constructed using standard techniques (Ausubel et al., supra, 1987) as follows: The large Clal-Asp718 fragment from tgCMV/CD was ligated to a synthetic DNA fragment (prepared by annealing oligonucleotides
  • Plasmid tgCMV/neo-CD was constructed using standard techniques (Ausubel et al., supra, 1987) as follows: The large Sphl-Sall fragment from tgCMV/neo was ligated to a Clal- Ncol fragment amplified from tgCMV/neo by PCR using oligonucleotides 5'-
  • NIH/3T3 cells were grown in Dulbecco Modified Eagle Medium (DMEM; available from Gibco Laboratories) supplemented with 10% bovine calf serum (Hyclone), 2 mM L-glutamine, 50 U/ml penicillin, and 50 ⁇ g/ml streptomycin at 37 °C in a humidified atmosphere supplemented with 10% CO2*
  • DMEM Dulbecco Modified Eagle Medium
  • Plasmid DNA 5 ⁇ g was added to 800 ⁇ l of cell suspension (8 x
  • the cells were returned to 10 cm dishes and grown in non- selective medium. After 24 hours, die cells were trypsinized, seeded at 6 x 10 cells/10 cm dish, and allowed to attach overnight. The non-selective medium was replaced with selective medium (containing 500 U/ml of Hm or 800 ⁇ g/ml of G-418), and selection was continued for 10-14 days. The plates were then fixed with methanol, stained with methylene blue and colonies were counted. The number of colonies reported in Table 1 is the average number of colonies per 10 cm dish.
  • Untransfected cells were not hygromycin resistant (Hm ) or G-418 resistant (G-418 r ).
  • the CD-neo fusion gene confers G-418 , but the neo-CD fusion gene does not.
  • the concentration of protein in the extract was determined using a Biorad protein assay kit. A 25 ⁇ l aliquot of cell extract (or an equivalent amount of protein in a volume of 25 ⁇ l)
  • CD activity but the activities of the CD-hygro and hygro-CD fusion genes were lower than that of the CD-neo fusion gene.
  • the retroviral plasmids tgLS(+)neo and tgLS(+)CD-neo consist of the following elements: the 5' LTR and sequences dirough the PstI site at nucleotide 984 of MoMSV (Van Beveren et al., Cell 27:91, 1981); sequences from the PstI site at nucleotide 563 to nucleotide 1040 of MoMLV (Shinnick et al., Nature 293:543, 1981); a fragment from tgCMV/neo or tgCMV/CD-neo, containing the neo or CD-neo coding regions, respectively; sequences from nucleotide 7764 and through the 3' LTR of MoMLV (Shinnick et al., supra, 1981); the Nrul- AlwNI fragment from pML2d (Lusky and Botchan, supra, 1981), containing the bacterial replication origin; the AlwNI-Aat
  • Plasmid tgLS(+)neo was constructed using standard techniques (Ausubel et al., supra, 1987) as follows: Plasmid tgLS(+)hygro was constructed first, by ligating an EcoRI-Clal fragment from tgLS(+)HyTK to an EcoRI-Asp718 fragment from tgCMV/hygro, and a synthetic DNA fragment (prepared by annealing oligonucleotides
  • Plasmid tgLS(+)neo was then constructed by replacing the Nhel-Hindm fragment spanning the hygro gene with a Nhel-Hindlll fragment amplified from pSV2neo (Southern and Berg, J. Mol. Appl. Gen. 7:327, 1982) by PCR using oligonucleotides
  • Plasmid tgLS(+)CD-neo was constructed using standard techniques (Ausubel et al., supra, 1987) as follows: The Nhel-Sall fragment spanning the HCMV IE94 promoter and human IL-2 cDNA from HyTK-CMV-IL2 was replaced wi ⁇ die Nhel-Sall fragment from tgCMV/CD-neo.
  • Figure 3 shows the proviral structures of the retroviral vectors tgLS(+)neo and tgLS(+)CD-neo.
  • LTR signifies the long terminal repeat segments of the retroviral vector
  • neo signifies the bacterial neomycin phosphotransferase gene
  • CD- neo represents the CD/neomycin phosphotransferase fusion gene.
  • the neo and CD-neo genes are operably linked to the LTR transcriptional control region.
  • the arrows show the direction ooff ttrraannsscciription from the transcriptional control regions.
  • A represents the polyadenylation sequence
  • Retroviral Vectors To derive stable NIH/3T3 cell lines infected wi ⁇ tgLS(+)neo and tgLS(+)CD-neo, the retroviral plasmid DNAs were transfected into ⁇ 2 ecotropic packaging cells. The transfected ⁇ 2 cells were then transferred to a 10 cm tissue culture dish containing 10 ml of complete growth medium supplemented with 10 mM sodium butyrate (Sigma Chemical Co.) and allowed to attach overnight. After 15 h, the medium was removed and replaced with fresh medium.
  • the medium containing transiently produced ecotropic virus particles was harvested, centrifuged at 2000 rpm for 10 minutes and used to infect NIH/3T3 cells. Exponentially dividing NIH/3T3 cells were harvested by trypsinization and seeded at a 4 density of 2.5 x 10 cells/35 mm well in two 6-well tissue culture trays. On the following day, the medium was replaced with serial dilutions of virus-containing, cell-free supernatant (1 ml/well) in medium supplemented with 4 ⁇ g/ml Polybrene hexadimethrine bromide (Sigma Chemical Co.). Infection was allowed to proceed overnight. Then the supernatant was replaced with complete growth medium. After a further 8-24 hours of growth, the infected
  • NIH/3T3 cells were selected for drug resistance to G-418 (Gibco) at a final concentration of
  • the cells were then centrifuged for 10 seconds at 14,000 rpm in an Eppendorf microfuge, resuspended in 100 ⁇ l of Tris buffer and subjected to five cycles of rapid freezing and thawing. Following centrifiigation for 5 min at 6,000 rpm in an Eppendorf microfuge, the supernatant was transferred to a clean tube. The concentration of protein in the extract was determined using a Biorad protein assay kit. A 25 ⁇ l aliquot of cell extract (or an equivalent
  • Plate a had NIH/3T3 cells grown in drug-free medium.
  • Plate b had NIH/3T3 cells grown in medium containing 800 ⁇ g/ml G-418.
  • Plate c had NIH/3T3 cells grown in medium containing 100 ⁇ g/ml 5-FC.
  • Plate d had NIH/3T3 cells infected widi tgLS(+)neo and grown in medium containing 800 ⁇ g/ml G-418.
  • Plate e had NIH/3T3 cells infected widi tgLS(+)neo and grown in medium containing 800 ⁇ g/ml G-418 and 100 ⁇ g/ml 5-FC.
  • Plate f had NIH/3T3 cells infected widi tgLS(+)CD-neo and grown in medium containing 800 ⁇ g/ml G-418.
  • Plate g had NIH/3T3 cells infected wim tgLS(+)CD-neo and grown in medium containing 800 ⁇ g/ml G- 418 and 100 ⁇ g/ml 5-FC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP94918041A 1993-05-21 1994-05-19 Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend Withdrawn EP0804590A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6638893A 1993-05-21 1993-05-21
US66388 1993-05-21
PCT/US1994/005601 WO1994028143A1 (en) 1993-05-21 1994-05-19 Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene

Publications (1)

Publication Number Publication Date
EP0804590A1 true EP0804590A1 (de) 1997-11-05

Family

ID=22069207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94918041A Withdrawn EP0804590A1 (de) 1993-05-21 1994-05-19 Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend

Country Status (5)

Country Link
EP (1) EP0804590A1 (de)
JP (1) JPH09500783A (de)
AU (1) AU6953394A (de)
CA (1) CA2163427A1 (de)
WO (1) WO1994028143A1 (de)

Families Citing this family (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204183A1 (en) * 1994-11-01 1996-05-09 Andrew Lawrence Feldhaus Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
CA2188575A1 (en) 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
AU7525496A (en) * 1995-10-23 1997-05-15 Betagene, Inc. Methods and compositions comprising glut-2 and glut-2 chimeras
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
WO2008121719A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
WO2005007857A1 (en) * 2003-07-21 2005-01-27 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
US8669109B2 (en) 2003-08-19 2014-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of producing proteins in Chinese hamster ovary (CHO) cells
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
CA2782619A1 (en) * 2005-07-15 2007-01-25 Medical Research Council Compositions and methods relating to orthogonal ribosome mrna pairs
US20070036770A1 (en) 2005-08-12 2007-02-15 Wagner Darrell O Biologic device for regulation of gene expression and method therefor
EP1941043B1 (de) 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Methode zur rekombinanten expression eines polyeptids
EP1945781B1 (de) 2005-10-28 2014-03-05 F.Hoffmann-La Roche Ag Proteinexpression in nagerzellen
CN101437933B (zh) 2005-12-28 2013-11-06 斯克里普斯研究所 作为药物靶标的天然反义和非编码的rna转录物
US20070190028A1 (en) 2006-02-13 2007-08-16 Jihong Qu Method and apparatus for heat or electromagnetic control of gene expression
CA2651478C (en) 2006-05-17 2015-02-03 Josef Endl Polypeptide producing cells
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
CN101687920B (zh) 2007-06-29 2013-06-19 弗·哈夫曼-拉罗切有限公司 导致免疫球蛋白生产改善的重链突变体
SI2592148T1 (sl) 2007-10-12 2018-12-31 F. Hoffmann-La Roche Ag Izražanje beljakovin iz več nukleinskih kislin
US20100272679A1 (en) 2007-12-14 2010-10-28 Penn Marc S Compositions and methods of promoting wound healing
CA2762118A1 (en) 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
KR20110091796A (ko) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
JP6091752B2 (ja) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
ES2560107T3 (es) 2009-02-12 2016-02-17 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
MX2011009752A (es) 2009-03-17 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
RU2537264C2 (ru) 2009-04-03 2014-12-27 Медикал Рисерч Каунсил Мутанты индуцируемой активацией цитидиндеаминазы (aid) и способы их применения
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
JP5931720B2 (ja) 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
CN103221541B (zh) 2009-05-28 2017-03-01 库尔纳公司 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
JP5944311B2 (ja) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
JP5907866B2 (ja) 2009-06-26 2016-04-26 クルナ・インコーポレーテッド ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
CN102712925B (zh) 2009-07-24 2017-10-27 库尔纳公司 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CN104313027B (zh) 2009-08-11 2018-11-20 库尔纳公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
EP2467482A4 (de) 2009-08-21 2013-12-11 Curna Inc Behandlung von chip (c-terminus des hsp70-interagierenden proteins)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen chip
JP5964232B2 (ja) 2009-08-25 2016-08-03 カッパーアールエヌエー，インコーポレイテッド ‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
CN102740894B (zh) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
DK2478107T3 (da) 2009-09-15 2019-01-02 Medimmune Ltd Celler til transient ekspression og anvendelser deraf
ES2664591T3 (es) 2009-09-25 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
DK2513310T3 (en) 2009-12-16 2018-02-05 Curna Inc TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
CA2782375C (en) 2009-12-23 2023-10-31 Opko Curna, Llc Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
ES2661387T3 (es) 2009-12-23 2018-03-28 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
JP5993744B2 (ja) 2009-12-29 2016-09-14 カッパーアールエヌエー，インコーポレイテッド 核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
EP2519634B1 (de) 2009-12-29 2016-06-01 CuRNA, Inc. Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
DK2519632T3 (en) 2009-12-31 2018-07-23 Curna Inc TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
KR101853509B1 (ko) 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
KR101854926B1 (ko) 2010-01-11 2018-05-04 큐알엔에이, 인크. 성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
ES2671877T3 (es) 2010-01-25 2018-06-11 Curna, Inc. Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
ES2600356T3 (es) 2010-02-22 2017-02-08 Curna, Inc. Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
WO2011127088A2 (en) 2010-04-05 2011-10-13 Eos Neuroscience, Inc. Methods and compositions for decreasing chronic pain
JP5978203B2 (ja) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
EP2957636B1 (de) 2010-05-03 2020-04-01 CuRNA, Inc. Behandlung von sirtuin 3 (sirt3)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt3
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
US8734780B2 (en) 2010-06-04 2014-05-27 Medtronic, Inc. Methods for treating cardiac pacing conditions
US20110305670A1 (en) 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
DK2585596T3 (da) 2010-06-23 2021-04-06 Curna Inc Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
GB2498325B (en) 2010-10-15 2018-05-02 Eos Neuroscience Inc Engineered human GRM6 enhancer sequence for use in eye therapies
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
ES2653247T3 (es) 2011-06-09 2018-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
MX365525B (es) 2011-09-06 2019-06-06 Curna Inc Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
EP2626369A1 (de) 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Gentechnisch veränderte mesenchymale Stammzellen und ihre therapeutische Verwendung
US20150071958A1 (en) 2011-11-30 2015-03-12 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
HUE040179T2 (hu) 2012-03-15 2019-02-28 Curna Inc Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
AU2013246034B2 (en) 2012-04-09 2017-12-07 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
KR20240136359A (ko) 2012-04-11 2024-09-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2013182553A2 (en) 2012-06-06 2013-12-12 Boehringer Ingelheim International Gmbh CELL ENGINEERING USING RNAs
PT3824905T (pt) 2012-08-20 2025-03-21 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapêutica celular
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
EP2970956A1 (de) 2013-03-11 2016-01-20 Novartis AG Verfahren zum screening von zellklonen
US20160331809A1 (en) 2013-03-15 2016-11-17 Juventas Therapeutics, Inc. The use of sdf-1 to mitigate scar formation
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
CN105339389B (zh) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
AU2014297966B2 (en) 2013-07-31 2017-10-26 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
KR20160079854A (ko) 2013-10-31 2016-07-06 프레드 헛친슨 켄서 리서치 센터 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도
WO2015092735A1 (en) 2013-12-20 2015-06-25 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3083677B1 (de) 2013-12-20 2019-08-28 Novartis AG Neuartige eukaryotische zellen und verfahren zur rekombinanten expression eines produkts von interesse
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
KR102307278B1 (ko) 2014-04-29 2021-09-30 노파르티스 아게 신규 척추동물 세포 및 관심 폴리펩티드의 재조합적 발현 방법
EP3149044B1 (de) 2014-06-02 2020-10-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimäre antigenrezeptoren zum targeting von cd-19
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
FI3757206T3 (fi) 2014-11-05 2024-06-19 Juno Therapeutics Inc Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
WO2016086227A2 (en) 2014-11-26 2016-06-02 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
CN107206025A (zh) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 用于过继细胞治疗的方法和组合物
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
SI3277321T1 (sl) 2015-04-01 2024-11-29 Anaptysbio, Inc. Protitelesa, usmerjena proti t-celičnemu imunoglobulinu in mucin protein 3 (tim-3)
JP6913026B2 (ja) 2015-04-15 2021-08-04 アナプティスバイオ インコーポレイティッド インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体
EP3995142A3 (de) 2015-04-29 2022-08-24 Fred Hutchinson Cancer Center Modifizierte hämatopoietische stamm-/vorläuferzellen und non-t effektorzellen sowie verwendungen davon
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP3147366A1 (de) 2015-09-25 2017-03-29 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Todesrezeptorbasierter selektionsmarker
CA3002745A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
WO2017068425A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
EP3384294B1 (de) 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Verfahren und zusammensetzungen in zusammenhang mit zelltherapieassoziierter toxizität
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
MA71266A (fr) 2016-03-22 2025-04-30 Seattle Children's Hospital(DBA Seattle Children's Research Institute) Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
JP2019513752A (ja) 2016-04-07 2019-05-30 ケース ウエスタン リザーブ ユニバーシティ 神経変性疾患を治療するためのｔｄｐ−４３のミトコンドリア局在化阻害剤
US11351270B2 (en) 2016-06-07 2022-06-07 University Of Iowa Research Foundation Junctophilin-2 fragments and uses therefor
JP7591342B2 (ja) 2016-06-08 2024-11-28 プレシゲン，インコーポレイテッド Ｃｄ３３特異的キメラ抗原受容体
AU2017301880C1 (en) 2016-07-29 2022-04-21 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
SG10202102061SA (en) 2016-08-29 2021-04-29 Univ Wayne State Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
CN109790214B (zh) 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
EP3519570B1 (de) 2016-09-29 2022-06-08 F. Hoffmann-La Roche AG Verfahren zur analyse und optimierung von genmanipulationsmodulen und transferansätzen
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
SG11201903282TA (en) 2016-10-13 2019-05-30 Juno Therapeutics Inc Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP3689419A1 (de) 2016-11-01 2020-08-05 AnaptysBio, Inc. Gegen t-zell-immunglobulin und mucin-protein 3 (tim-3) gerichtete antikörper
CA3045323A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
BR112019014169A2 (pt) 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-tim-3
JP7288401B2 (ja) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US12440578B2 (en) 2017-02-22 2025-10-14 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
US10828330B2 (en) 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
AU2018251188A1 (en) 2017-04-14 2019-10-31 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
AU2018265893B2 (en) 2017-05-12 2021-10-07 Ion Channel Innovations, Llc Compositions and methods for treating idiopathic overactive bladder syndrome and detrusor overactivity
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
WO2018223098A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
JP2020522489A (ja) 2017-06-02 2020-07-30 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いる処置のための製造物品および方法
JP7262403B2 (ja) 2017-06-07 2023-04-21 プレシゲン，インコーポレイテッド 新規の細胞タグの発現
US20200230205A1 (en) 2017-07-11 2020-07-23 Case Western Reserve University Compositions and methods for treating myelin disorders
WO2019032927A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
SG11202000966XA (en) 2017-08-11 2020-02-27 Boehringer Ingelheim Int Integration sites in CHO cells
WO2019070638A1 (en) 2017-10-02 2019-04-11 Astrazeneca Ab CELL LINES AND METHODS FOR INCREASED PROTEIN PRODUCTION
MA50613A (fr) 2017-10-03 2020-08-12 Editas Medicine Inc Molécules de liaison spécifique à l'hpv
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
IL314393A (en) 2018-03-06 2024-09-01 Precigen Inc Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
US12186343B2 (en) 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
WO2019178267A2 (en) 2018-03-13 2019-09-19 University Of Iowa Research Foundation Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
AU2019301053A1 (en) 2018-07-09 2021-01-28 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2020033916A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
AU2019339464A1 (en) 2018-09-11 2021-03-25 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
CN112912392B (zh) 2018-10-26 2024-08-02 豪夫迈·罗氏有限公司 利用重组酶介导的盒式交换的多特异性抗体筛选方法
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
KR20210111247A (ko) 2018-11-08 2021-09-10 주노 쎄러퓨티크스 인코퍼레이티드 치료 및 ｔ 세포 조절을 위한 방법 및 조합
KR20210094567A (ko) 2018-11-14 2021-07-29 유로반트 사이언시즈 게엠베하 평활근 기능장애의 치료를 위한 조성물 및 방법
EP3980544A1 (de) 2018-12-21 2022-04-13 F. Hoffmann-La Roche AG Gezielte integration von nukleinsäuren
AU2020215576A1 (en) 2019-01-29 2021-07-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
EP3947437A1 (de) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Verfahren zur erzeugung einer fcrn-exprimierenden zelle durch gezielte integration mehrerer expressionskassetten in einer definierten organisation
SG11202111360YA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
WO2020223571A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
WO2020247648A2 (en) 2019-06-05 2020-12-10 Anaptysbio, Inc. Pd-1 agonist and method of using same
WO2020254356A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020294879A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
EP3986925A1 (de) 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Verfahren zur herstellung einer trivalenten antikörperexprimierenden zelle durch gezielte integration mehrerer expressionskassetten in eine definierte organisation
CA3140297A1 (en) 2019-06-19 2020-12-24 Simon Auslaender Method for the generation of a protein expressing cell by targeted integration using cre mrna
CA3140192A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
WO2020264253A1 (en) 2019-06-26 2020-12-30 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
JP7450647B2 (ja) 2019-06-26 2024-03-15 エフ． ホフマン－ラ ロシュ アーゲー Ｓｉｒｔ－１遺伝子ノックアウトを有する哺乳類細胞株
WO2021041994A2 (en) 2019-08-30 2021-03-04 Juno Therapeutics, Inc. Machine learning methods for classifying cells
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
US12522645B2 (en) 2019-11-05 2026-01-13 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
US12570749B2 (en) 2019-12-06 2026-03-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to GPRC5D-targeted binding domains and related compositions and methods
US20230069055A1 (en) 2020-01-21 2023-03-02 Bolt Biotherapeutics, Inc Anti-pd-l1 antibodies
AU2021211669A1 (en) 2020-01-21 2022-08-25 Bolt Biotherapeutics, Inc. Anti-PD-L1 antibodies
KR20230005907A (ko) 2020-05-01 2023-01-10 볼트 바이오테라퓨틱스 인코퍼레이티드 항-dectin-2 항체
EP4150057A2 (de) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Verfahren zur herstellung von donor-batch zellen, die einen rekombinanten rezeptor exprimieren
KR20230027043A (ko) 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
WO2022018178A1 (en) 2020-07-24 2022-01-27 F. Hoffmann-La Roche Ag Method for the expression of an antibody-multimer-fusion
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
AU2021319103A1 (en) 2020-07-30 2023-02-09 Anaptysbio, Inc. Anti-interleukin 36 receptor (IL-36r) therapy for ichthyosis
TW202223092A (zh) 2020-09-24 2022-06-16 瑞士商赫孚孟拉羅股份公司 具有基因剔除的哺乳動物細胞株
CA3197726A1 (en) 2020-10-15 2022-04-21 Simon Auslaender Nucleic acid constructs for simultaneous gene activation
HRP20250766T1 (hr) 2020-10-15 2025-08-15 F. Hoffmann - La Roche Ag Konstrukti nukleinske kiseline za transkripciju va rna
CA3196493A1 (en) 2020-10-23 2022-04-28 Martin Edward DAHL B and t lymphocyte attenuator (btla) modulators and method of using same
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022116086A1 (en) 2020-12-03 2022-06-09 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
CN116670282A (zh) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 靶向xbp1的寡核苷酸
EP4314814A1 (de) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Verfahren zur bestimmung der wirksamkeit einer therapeutischen zellzusammensetzung
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
EP4148067A1 (de) 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Verfahren zur expression einer antikörper-multimer-fusion
WO2023081752A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023077343A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
JP2025500443A (ja) 2021-12-22 2025-01-09 ジェネンテック， インコーポレイテッド 多重ベクターリコンビナーゼ媒介カセット交換
KR20240141180A (ko) 2022-01-14 2024-09-25 사카로 아이엔씨. 탈-n-아세틸화 폴리시알산(dpsa) 결합제 및 그의 사용 방법
KR20240158888A (ko) 2022-02-28 2024-11-05 얀센 바이오테크 인코포레이티드 다발성 골수종을 위한 bcma를 표적으로 하는 car-t 세포 요법
US20250213721A1 (en) * 2022-03-24 2025-07-03 Memorial Sloan-Kettering Cancer Center Compositions including ifne and uses thereof
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
JP2025513335A (ja) 2022-04-19 2025-04-24 エフ． ホフマン－ラ ロシュ アーゲー 改良された産生細胞
KR20250007603A (ko) 2022-04-27 2025-01-14 아납티스바이오, 아이엔씨. B 및 t 림프구 감쇠제(btla) 조절제 및 이를 사용하는 방법
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
JP2025517572A (ja) 2022-06-03 2025-06-05 エフ． ホフマン－ラ ロシュ アーゲー 改良された産生細胞
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
US20250382640A1 (en) 2022-06-29 2025-12-18 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
CN120530136A (zh) 2022-11-07 2025-08-22 安奈普泰斯生物有限公司 Cd122结合剂和其使用方法
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
EP4619511A1 (de) 2022-11-15 2025-09-24 Genentech, Inc. Kombinierte transposonvermittelte integration und gezielte integration von nukleinsäuren in wirtszellen
IL320073A (en) 2022-11-23 2025-06-01 Hoffmann La Roche Method for increasing recombinant protein expression
EP4630782A1 (de) 2022-12-09 2025-10-15 Juno Therapeutics, Inc. Maschinenlernverfahren zur vorhersage des zellphänotyps mittels holografischer bildgebung
US20240240175A1 (en) 2023-01-12 2024-07-18 Genentech, Inc. Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids
EP4658675A1 (de) 2023-02-03 2025-12-10 C3S2 GmbH Verfahren zur nichtviralen herstellung von manipulierten immunzellen
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
CA3205511A1 (en) 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor
AU2024269420A1 (en) 2023-05-11 2025-11-27 Case Western Reserve University Anxiolytic therapy
KR20260026101A (ko) 2023-05-23 2026-02-25 주노 쎄러퓨티크스 인코퍼레이티드 T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
WO2024243594A1 (en) 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells
AU2024287644A1 (en) 2023-07-12 2026-01-29 Saccharo, Inc. De-n-acetylated polysialic acid (dpsa) binding agent, conjugates, and method of using same
CN121666400A (zh) 2023-08-09 2026-03-13 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法和用途
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
TW202530413A (zh) 2023-10-05 2025-08-01 美商健生生物科技公司 用於生產ｃａｒ－ｔ細胞藥品之慢病毒製造的改良方法
WO2025085705A1 (en) 2023-10-18 2025-04-24 Genentech, Inc. Retroviral-like particle-reduced chinese hamster ovary production cell lines
US20250207106A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Composition and methods for adeno-associated virus producing stable human embryonic kidney-293 cell lines
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
US20250269024A1 (en) 2024-02-05 2025-08-28 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20250339527A1 (en) 2024-03-12 2025-11-06 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025212519A1 (en) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025262318A1 (en) 2024-06-21 2025-12-26 Boehringer Ingelheim International Gmbh Multi-hydrolase knockout

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
AU650085B2 (en) * 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
AU675948B2 (en) * 1992-05-01 1997-02-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Bystander effect tumoricidal therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9428143A1 *

Also Published As

Publication number Publication date
AU6953394A (en) 1994-12-20
JPH09500783A (ja) 1997-01-28
WO1994028143A1 (en) 1994-12-08
CA2163427A1 (en) 1994-12-08

Similar Documents

Publication Publication Date Title
WO1994028143A1 (en) Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU650085B2 (en) Bifunctional selectable fusion genes
US6312948B1 (en) Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells
US6027722A (en) Vectors for gene transfer
US6955919B2 (en) Lentiviral packaging cells and uses therefor
WO1994020608A1 (en) Improved vectors for gene therapy
US5698446A (en) Methods and compositions for inhibiting production of replication competent virus
Sokolic et al. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression
Couture et al. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression
US6319707B1 (en) Cap-independent multicistronic retroviral vectors
US7056730B2 (en) Expression of heterologous genes from an IRES translational cassette in retroviral vectors
WO1996035798A1 (en) Improved retroviral vectors, especially suitable for gene therapy
US6555370B1 (en) Bifunctional selectable fusion genes
Kaptein et al. Expression pattern of CD2 locus control region containing retroviral vectors in hemopoietic cells in vitro and in vivo
IL116216A (en) Eukaryotic cell lineages for recombinant viral retroviral RNA storage, using trans-expression vectors used to complete the trans
CA2199131C (en) Retroviral vector hybrids and the use thereof for gene transfer
US20030190753A1 (en) Vectors for gene transfer
Ricciardone Induction of methotrexate resistance by retroviral-mediated transfer of a mutant dihydrofolate reductase gene
Baranick Characterization and utilization of simple replication-competent retroviral vectors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19951222